Evidence map›Paper›PMID 41090357›Full record

ArticleThe Journal of clinical investigation2025

Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice.

Vincent C Auyeung, Tavienne L Steinberg, Alina Olivier, Luka Suzuki, Mary E Moreno, Imran S Khan, Michael S Downey, Maike Thamsen, Lu Guo, Dustin J Maly and 3 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. New and emerging therapies in type 1 diabetes mellitus.The Journal of clinical investigation · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vincent C AuyeungDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Tavienne L SteinbergDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Alina OlivierDiabetes Center.
Luka SuzukiDepartment of Medicine.
Mary E MorenoDepartment of Medicine.
Imran S KhanCardiovascular Research Institute.
Michael S DowneyDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Maike ThamsenDiabetes Center.
Lu GuoDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Dustin J MalyDepartment of Chemistry, University of Washington, Seattle, Washington, USA.
Bradley J BackesDepartment of Medicine.
Dean SheppardDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Feroz R PapaDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.

Funding

Interventional Targeting of the IRE1alpha-TGFbeta signaling loop in pulmonary fibrosisR01HL145037 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PAPA, FEROZ R, SHEPPARD, DEAN · 2019 to 2022
$3.0M
Partial Antagonists of IRE1 RNase—‘PAIR’s—to treat Type 1 DiabetesU01DK123609 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALY, DUSTIN J, PAPA, FEROZ R · 2019 to 2022
$2.9M
IRE1α mediated dysregulation of the pulmonary epithelium in lung fibrosisK08HL157654 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AUYEUNG, VINCENT CHURK-MAN · 2021 to 2025
$874k
NHLBI NIH HHS K08 HL157654NHLBI NIH HHS R01 HL145037NIDDK NIH HHS U01 DK123609
6 · The paper itself

Abstract

Stress-induced epithelial plasticity is central to lung regeneration, fibrosis, and malignancy, but how cellular stress leads to differentiation is incompletely understood. Here, we found a central role for IRE1α, a conserved mediator of the unfolded protein response (UPR), in stimulating the plasticity of alveolar type 2 (AT2) cells. In single-cell RNA-seq, IRE1α activity was associated with loss of AT2 identity and progression toward a damage-associated transitional state unique to fibrosis. AT2 plasticity required destructive regulated IRE1α-dependent decay (RIDD), which we demonstrated by deploying PAIR2, a kinase modulator that inhibits RIDD while preserving IRE1α's adaptive XBP1 mRNA splicing activity. In vivo, selective inhibition of RIDD with PAIR2 reduced AT2 differentiation into profibrotic transitional cells and protected mice from bleomycin-induced pulmonary fibrosis. Mechanistically, we identified the Fgfr2 mRNA as a direct and regulated substrate for IRE1α's RNase in primary AT2 cells and in a biochemically reconstituted cell-free system. Loss of Fgf signaling caused AT2 differentiation, while gain of signaling protected cells from IRE1α-induced differentiation. We propose that IRE1α downregulates Fgf signaling through RIDD, provoking loss of AT2 identity and differentiation towards a profibrotic phenotype. Thus, IRE1α's RIDD activity emerges as a novel target for treatment of pulmonary fibrosis and potentially other diseases driven by aberrant epithelial cell plasticity.

Indexed as

Alveolar Epithelial CellsEndoribonucleasesProtein Serine-Threonine KinasesPulmonary FibrosisRNA StabilityAnimalsBleomycinCell DifferentiationHumansMiceReceptor, Fibroblast Growth Factor, Type 2Unfolded Protein ResponseX-Box Binding Protein 1BleomycinEndoribonucleasesErn1 protein, mouseProtein Serine-Threonine KinasesReceptor, Fibroblast Growth Factor, Type 2X-Box Binding Protein 1Xbp1 protein, mouseCell stressFibrosisProtein kinasesPulmonologyStem cellsTherapeutics

Identifiers

PMID41090357
PMCPMC12520674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.